Alembic Pharmaceuticals is currently trading at Rs. 522.00, up by 0.30 points or 0.06% from its previous closing of Rs. 521.70 on the BSE.
The scrip opened at Rs. 522.40 and has touched a high and low of Rs. 526.95 and Rs. 505.00 respectively. So far 1217 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 709.30 on 23-Mar-2017 and a 52 week low of Rs. 469.75 on 20-Sep-2017.
Last one week high and low of the scrip stood at Rs. 575.90 and Rs. 505.00 respectively. The current market cap of the company is Rs. 9708.57 crore.
The promoters holding in the company stood at 72.68%, while Institutions and Non-Institutions held 14.34% and 12.98% respectively.
Alembic Pharmaceuticals’ associate company - Rhizen Pharmaceuticals S.A. (Rhizen) has been granted orphan-drug designation by the US Food and Drug Administration (USFDA) for the active moiety of Tenalisib, the company’s highly selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of peripheral T-cell lymphoma (PTCL).
Tenalisib is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
